The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
Oncogenic mutations of isocitrate dehydrogenases 1 and 2 result in the production of the oncometabolite R-2-hydroxyglutarate. Here the authors show that the oncometabolite promotes mTOR activation in a PTEN/PI3K-independent manner by regulating DEPTOR stability via inhibition of KDM4A activity.
Guardado en:
Autores principales: | Mélissa Carbonneau, Laurence M. Gagné, Marie-Eve Lalonde, Marie-Anne Germain, Alena Motorina, Marie-Christine Guiot, Blandine Secco, Emma E. Vincent, Anthony Tumber, Laura Hulea, Jonathan Bergeman, Udo Oppermann, Russell G. Jones, Mathieu Laplante, Ivan Topisirovic, Kevin Petrecca, Marc-Étienne Huot, Frédérick A. Mallette |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2016
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9dd294f273304449b3e2d5962e483354 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Detection of Nail Oncometabolite SAICAR in Oral Cancer Patients and Its Molecular Interactions with PKM2 Enzyme
por: Rushikesh Patel, et al.
Publicado: (2021) -
An l-2-hydroxyglutarate biosensor based on specific transcriptional regulator LhgR
por: Zhaoqi Kang, et al.
Publicado: (2021) -
Widespread bacterial lysine degradation proceeding via glutarate and L-2-hydroxyglutarate
por: Sebastian Knorr, et al.
Publicado: (2018) -
Treatment with sodium (S)-2-hydroxyglutarate prevents liver injury in an ischemia-reperfusion model in female Wistar rats
por: Eduardo Cienfuegos-Pecina, et al.
Publicado: (2021) -
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Ovidiu C. Andronesi, et al.
Publicado: (2018)